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many cases   inappropriate  to  tackle   the dauntingly  complex problems related to  the drug design.  Thus,  a  
continuous   feedback   with   experiments   is   required   but   also   the   appropriate   combination   of   different 
computational strategies might be helpful.
This  work represents   the application of  computational   techniques,  such as  docking,  molecular  dynamics,  
algorithms to calculate free energy of binding of ligands into the binding pocket ( MM­PBSA) and algorithms  
to  study   rare  events   (like    unbinding  of   ligand   from the  binding   site,  Metadynamics,  etc.)   to  explore,  at  
microscopic   level,   the key  pattern of   interaction between protein  and  ligand,   to  understand  the effect  of 
mutations, to get an insight of the full and undocking path and to calculate binding energetics. 
In this thesis, polymerases of three positive strand RNA viruses, viz,  Hepatitis  C Virus (HCV),  Bovine Viral  
Diarrhea Virus (BVDV) and Human Immunodeficiency Virus (HIV) have been targeted with an aim to come 
out with more  potent antivirals effective against wide range of resistant mutations. These viruses have created 
























































































































































































































Figure4: A)­The two dimensional Free energy surface(FES) of PS999'S     undocking process, as a function of  
gdist  and  HpH  contacts. Each line correspond to 1kcal/mol. where each color and each line correspond to 
1kcal/mol  A)­this   panel   represent   the   FES   of   PS999,   representation   two  deep  minima  while   panel    B)­ 
Evolution of the center of mass of  PS999 during the metadynamics simulations of the undocking process. The 
residues  of   the  putative  binding  site  are  highlighted   in   licorice.  C)­  Pictorial   representation of  closing of 
binding site in mini2 (green in color), as compared to the mini1(purple and transparent ).
Figure5: A)­The two dimensional Free energy surface(FES) of PS1036'S    undocking process, as a function of 
gdist  and  HpH  contacts. Each line correspond to 1kcal/mol. where each color and each line correspond to 
1kcal/mol  A)­this  panel   represent   the  FES  of  PS1036,   representation   two  deep  minima  while  panel  2B)­  
represent the FES of PS1036 with only one minima. B)­ Evolution of the center of mass of A)­ PS1036 during 






Figure1.  Ribbon   representation   of   the   overall   structure   of   HCV   NS5B   polymerase   in   blue   along   with 
transparent surface view in white. Solid surface representations of four allosteric binding sites are also shown.  
The dark red colored surface corresponds to the thumb allosteric binding pocket of indole group “siteA”; the 
























residues   are   shown   here   using   sticks   representation(basic:blue,   acidic:red,   hydrophobic:white)   while 
compounds are in ball and stick in cyan color. In panel (A) and (B)Interaction map and interaction energy of 






residues   are   shown   here   using   sticks   representation(basic:blue,   acidic:red,   hydrophobic:white)   while 
compounds are in ball and stick in cyan color. In panel (A) and (B)Interaction map and interaction energy of 
PS1097;  panel   (C)  and  (D  )   Interaction map and  interaction  energy  of  PS1101 and panel   (E)  and  (F)  are 
Interaction map and interaction energy of PS1126. Average ligand­residue interaction energies in kcal/mol 
over compound PS1097, PS1101 and PS1126 for the residues that contribute most to the ligand ­surrounding. 
Figure7:     Key   structure   playing   crucial   role   in   polymerization.  These   five   structurally   and   functionally 






Table1:Approved   antiviral   drugs   against  HCV.   Adapted   from:  HCV   Advocate;   July   24,   2010;Hepatitis   C  
treatment in current clinical development; Alan Franciscus.
Table2:Approved antiretroviral drugs. Adapted from: Drugs Used in the Treatment of HIV Infection, U.S. FDA, 




























































Another   viral  pathogen,  Bovine   viral   diarrhoea   virus   (BVDV),  has   created  havoc  by   affecting   cattles  and 




Figure1:  Global  variations   in  age  adjusted   incidence  rates  of   liver  cancer,  prevalence of  chronic  HCV  infection  and chronic  HBV  
infection. Adapted from: Yang, J.  D. & Roberts, L. R. (2010) Hepatocellular carcinoma: a global view Nat, Rev. Gastroenterol.  Hepatol.  
doi:10.1038/nrgastro.2010.100










consequence of   treatment  failure.  Viral   infection is  characterized by a very high replication rate,  with  the 
production of 1 to 10 billion new virus particles per day in an untreated infected individual . Moreover, viruses  
lacks   proof­reading   functionality,   and   this   results   in   an   average   error   rate   per   detectable   nucleotide 
incorporated of 1/1700 .  Hence focus is needed on the development of antivirals effective against wide range 
of   resistant  mutation  as  well   as   coming  up  with  combination   therapy  as   the   'High  active  anti   retroviral  
Therapy' (HAART) in case of HIV infection. 
Life cycle of viral life cycle include various steps, all of which can be targeted for the development of antiviral  
therapy.  These   steps  broadly   encompass   viral   attachment,   entry,   and   fusion;   viral  RNA   translation;  post  
translational  processing;  HCV replication;  and  viral  assembly  and  release.  Among  the  other   targets,  Viral 
polymerase, which is strictly required for viral replication, has been the focus of intense drug discovery activity  
as  they are considered as significant  targets  for  therapeutic   intervention.  Several  reasons that makes viral 
















have   remained  unchanged   certain   sequences  of   their  RdRp,  by   virtue  of   the   key   role   in   the  process  of  
transcription and replication of viral genomes. However, the effectiveness of nucleoside analogues has been 
reported   to   be   compromised   due   to   the   generation   of   resistant  mutants   and   the   adverse   side­effect,  
necessitating   the   development   of   new   inhibition   targets   and   inhibitors   of  NS5B.   Accordingly,   the   non­










effective  antivirals  against   the  former mentioned pathogens.  Recent  success  obtained  in combating these  
viruses by targeting NNI against  the viral polymerases have prompted me to study and explore in depth the  
15







Due to   the recent  developments   in   the  field of  chemistry,  pharmacology,  microbiology,  biochemistry  and 
biophysics, development of new antivirals is no longer confined to the imagination of chemist but results from 















To gain   insight   into  such  processes,   the   three­dimensional   structure of  a   folded amino acid  sequence,  a  
functional   protein,   is   necessary.   The   structure   determination   of   proteins   or   nucleic   acids   is   based   on 
experimental techniques such as X­ray crystallography[18,19] or nuclear magnetic resonance (NMR),[20,21] 
which   have  made   remarkable   progress   in   solving   high­resolution   structures   over   the   past   years.   Such 
structures   are   archived   and   accessible   via   the   RSCB   Protein   Data   Bank.[22]     Furthermore,   theoretical 
approaches for structure prediction from amino acid sequences are under constant development and have  
been monitored by CASP (Critical Assessment of Structure Prediction) over the last 14  years.









NMR   relaxation  measurements[26,   27,   28,   29]   have   been   used   to   probe   protein   dynamics   on   pico­   to 
nanosecond   and  micro­   to  millisecond   time­scales,   and   thus   fail   to   reveal   dynamics   on   the   nano­   to  
microsecond time scale.
Such  time­resolved  dynamics   is  needed   to  understand  molecular   recognition mechanisms,  which enable 
specific binding of drugs to target proteins, or binding of polymerases to antivirals leading to inhibition of the  
polymerase  process.  Moreover,   as  has  been  shown  in  a   recent   study  of  ubiquitin  with  a  combination  of  





















interactions   are   calculated   for   the   different   conformations   and   a   scoring   function   evaluates   the   ligand 
conformations,  which  energetically   fit  best.   Such  a  challenging   issue  might   in  principle  be  addressed  at 
different  levels  of complexity  for  the physical  description of  the system under investigation. Nevertheless,  
molecular docking is always concerned with two closely related sub­problems, [35,34] namely, the sampling of 
the conﬁgurational space (pose generation), and the evaluation of the stability of the intermolecular complex  
generated   at   the   previous   step   (pose   scoring).   The  most   popular   docking   programs   employed   by   the  
pharmaceutical community usually trade accuracy for speed.
Several applications with different scoring functions, such as Autodock,[36] FlexX,[37], Gold,[38] or GLIDE,[39]  
have   been   developed   over   the   past   years.   It   is   common   to   these   applications   that   an   implicit   solvent 
environment is used and the flexibility of the protein is often neglected. Despite the advantage to screen large 

















molecular biology and pharmaceutical issues    .  Using MD simulations the thermodynamic properties and 
time­dependent phenomena (i.e. kinetic) can be studied and this allows an understanding of various dynamic  
aspects   of   biomolecular   structure,   protein­ligand   recognition   and   function.  The  major   strengths   of  MD 
simulations  are   the possibility  of   its  combination with  statistical  mechanics,  which connects  microscopic  
simulation   with   macroscopic   observables.   Statistical   mechanics   can   provide   a   rigorous   framework   of 
mathematical expressions that can relate the distribution and motion of atoms with macroscopic observables 
such as temperature, pressure, heat capacity and free energies.  In this way we are able to predict, for instance,  





Despite  being powerful   technique  MD has   its  own set  of   limitations.  MD simulations  allow  investigating 
processes  occurring  on   timescales  of  ~100ns.  However,  many   interesting  and   relevant  biological  process 
happen on  time scales   that  are  orders  of  magnitude   larger,  and are   therefore  termed as   rare  events.  For 
example,  the association and dissociation   of   ligand from its  binding cavity  (~µs),  protein folding (µs­few 
seconds),  protein­protein  interactions,   transport of  molecules  across membrane channels  (order ~µs) and 
many  others.  Over   the  years,  we  have  observed  an  astounding   increase   in   computer  power   (Blue   gene,  
DESRES), which promise to increase utility of MD simulations to investigate more and more complex systems 





















energy   at   a   quantitative   level   into   its   enthalpic   and   entropic   contributions   of   the  poses   obtained   from 
metadynamics.  MM/PBSA    is  held   to  be  one  of   the  more  computationally   tractable  means  of  obtaining 











































































triazole,   imidazole   or   pyrazine   (obtaining   triazolo[4,5­g]quinolines,   imidazo[4,5­g]quinolines   and 
pyrido[2,3­g]quinoxalines   respectively),   has   been   discovered.   In   particular   the   activity   of   the   title 
compounds were evaluated in cell culture systems against YFV (as viruses representative of Flaviviruses) 




the   inhibition  of   the   enzyme  target.  Overall,   by   these  experiments   the   imidazo[4,5­g]quinoline   (2h) 
emerged as  a  potent  BVDV polymerase  inhibitor  endowed with  IC50 = of  0.06 µM. Herein,  we have 











1. Identified   Binding   cavity   for   leads   belonging   to   pyridoxoquinoxaline(PS1036)   as   well   as 
imidazoquinoline(PS999) derivative in BVDV RdRp. The choice for the study of the leads was based on  
the knowledge of the resistant mutations against these compound.










1. Conglomeration   of   resistant   mutation   of   different   classes   of   compounds(in   this   work, 
pyridoxoquinoxalines   and   imidazoquinoline)   in   the   finger  domain  of  BVDV RdRp   indicated   that   the 
binding site of NNI may lye in the finger domain.  We performed extensive computational studies and  























build  a  microscopically  well­funded picture to  elucidate     the  mode of  action of  compounds  and  thereby 
providing clues for rational drug design.
Results: 
1. A blind docking procedure was applied  in all   four well  known binding sites  reported for  different 
classes of NNIs in HCV RdRp, to obtained the most prominent binding pocket for compound PS1097  
(Pyridoxiquinoline) and compound PS1126 (Imidazoquinoline) and PS1101(Phenanthrolines).





1. We   identified   probable   binding   cavity   for   NNIs   belonging   to   three   different   classes 
Pyridoxoquinoxaline,   Imidazoquinoxaline   and   phenonthrolines.   This   was   an   encouraging 
performance,   given   that   all  molecular  modeling   studies  were   performed   in   the   absence   of   any 
available crystal structure of the protein in complex with these  classes of  inhibitors. 










Bovine  viral  diarrhea  virus   (BVDV)   is   a  Pestivirus  of   the  Flaviviridae  family  and  represents  a  major  viral 








aqueous   solution.  Then,   we   selected   representative   equilibrium   conformations   by   performing   a   cluster 
analysis,  and ran docking calculations of 277G on representative of the 5 most populated clusters of each  








target of our  lead benzimidazole compound 227G. Here,  we performed a multidisciplinary computational  














mutation on the structure of   the APO and HOLO proteins with respect  to  the wild type one.  The 
22










presence of   the  long side chain of  M261)   in  COMPLEXm, 227G is  not  stable   in  the  initial  
docking pose, but moves and reorients itself many times until finds a stable position. 
















of   the   binding   free   energies   linearly   correlate   very   well   with   those   derived   from   the   corresponding 
experimental  data,  suggesting that  the newly proposed protocol  may be used as  generalized approach to 
predict drug resistance associated with mutation I261M. Because it is essentially important for understanding  
the structure­resistance correlation and for structure based drug design to develop an effective computational  








some   local   transient   binding   site,  which  was  barely  noticed  by   x­ray   and  other   techniques.  The 


















The  present   calculations  provide  a  validation  of   the  combination  of  docking,  MD as  a  powerful   tool   in  
























ASCC16912 Imido PS11262.0 MC13460.005
Imido PS9990.6 Pyrido PS10970.6 MC11950.05
















• Binding mode validation 
• Binding Affinity
Metadynamics
















































































intramembrane arrow, cleavage by the signal  peptide peptidase.  The transmembrane domains of  E1 and E2 are shown after  signal­
































Before Tat  is  present,  a  small  number of RNA transcripts will  be made, which allow the Tat protein to be  








viral   particles.   In   the   absence   of  Vif,   the   produced   viral   particles   are   defective,   while   the   cell­to­cell  
transmission of virus is not affected significantly. Found in almost all lentiviruses, Vif is a cytoplasmic protein,  















lentiviruses.  Other   forms   of  Nef   are   known,   including   nonmyristoylated   variants.  Nef   is   predominantly  




























the   presence   of   two   extended   loops,   the   fingertips,   that   connect   the   fingers   and   thumb   domains   and 
completely encircle the active site cavity, to which the RNA template and the nucleoside triphosphate (NTP) 
substrates have access through two positively charged tunnels [64]. 
The  palm  sub­domain  (residue 188  to 227,  287 to  370)  constitutes   the catalytic   site  of   the molecule  and 
contains the residues responsible for the nucleotidyl transfer reaction within the D­(X)4­D and the GDD motif.  












structure are a  ­hairpinβ  ( ­loop), protruding from the thumb into the active site, and a β C­ terminal region, 
located immediately before the transmembrane domain, that folds from the surface of the thumb towards the  
active site and establishes a series of hydrophobic interactions with a shallow pocket comprised between the  

















channel may be limited  [73,74]. The remainder of the finger domain is comprised of a  ­strand­rich region ( ­β β
fingers) and an  ­helix­rich region ( ­fingers) close to the palm domain. Although there is   little sequenceα α  
identity,   the   topology   of   the   fingers   domain,   excluding   the   finger­tips,   is   similar   to   that   of   other   viral  
polymerases,  making  possible   the structural  alignment  of   the  BVDV,  HCV,  calicivirus,  and  6  polymeraseφ  




sheet flanked by two  ­helices on one side and an additional  ­helix on the other side of the  ­sheet, nestedα α β  
between the palm and thumb domains. Compared to HCV polymerase, BVDV polymerase has a small  ­helixα  






eight  ­helices and five  ­strands and is larger than the thumb domain of other viral RdRps  Although there isα β  
some structural similarity between the HCV and BVDV thumb domains, the overall topology is rather different. 
The BVDV polymerase thumb domain possesses a structural element (‘‘the  ­thumb region’’) in which two  ­β β
strands  and  their  connecting  loops   form a  layer   that  occludes  the active  site  cavity.  The  ­thumb regionβ  








required   for  binding  proteins   in   the   replication  complex   [83].  The  ordered  part  of   the  N­terminal   region 
(residues 92–138) folds into a separate domain. The N­terminal domain is situated over the thumb domain,  
interacting with the fingertip region and thumb domain through a  ­hairpin motif. The  ­hairpin motif pointsβ β  
toward the template channel and partially occludes the channel entrance, possibly explaining why some N­
terminal   truncated   proteins   have   greater   polymerase   activity   than  wild   type   [81].  The   entrance   to   the 
template­binding channel created by the hairpin motif of the N­terminal domain is highly positively charged. 
An equivalent positively charged surface at the entrance to the channel was found in  6 polymerase, where itφ  








































virus   replication.   Upon   entry   into   the   cells,   nucleoside   analogues   are   first   converted   to   nucleotide 
triphosphates   (NTP).   The   unnatural   nucleoside   inhibitors   can   serve   as   competitive   substrates   for   the 
polymerase and can be incorporated into the nascent chain by the viral polymerase. This incorporation can  










the  enzyme’s  active   site,  which   is  more  conserved  and   less  genetically   variable   than   the  allosteric   (non­
catalytic)   sites  bound by non­nucleosides.  Anyway mutation may not  be  the only  resistance  mechanism. 







panel)   (Valopicitabine;  University  of  Cagliari/Idenix/Novartis)   [97].  A  component  of  NM 283   is   the  orally 
administrable   3’­O­valine   ester   of   2′­C­methyl­cytidine,   NM   107   (Fig   8   right   panel).   NM   107,   once 
phosphorylated intracellularly to its 5’ triphosphate metabolite, is initially known to be effective against BVDV. 
Later,  a replicon cell   lines­based assay revealed it  to be effective against  HCV. NM 283 is  effective against  
replicons originating from different HCV strains . Replicons resistant to 2’­C­methylcytidine contain the S282T 





Apart from NM283 other 2 ­methyl nucleosides that selectively inhibit of HCV replication are 2 ­O­methyl­′ ′





Lastly, RG7128 (Roche/Pharmasset),  a 2 ­modified nucleo­side analogue, has recently entered early clinical′  
trials. RG7128 is an oral prodrug of 2 ­deoxy­2 ­fluoro­2 ­C­methyl­cytidine, a pyrimidine nucleoside analogue′ ′ ′  
that  was  shown  to  act  as  a  non­obligate  chain   terminator  of   the  NS5B  polymerase  activity   [102]  and   to 
efficiently inhibit the replication of HCV RNA in hepatoma cell lines[Table 1] [103] 






Non­nucleoside   inhibitors   are   the  most  diverse  of   the   known  HCV  NS5B   inhibitors.  They   act  mostly   as  
allosteric inhibitors and interfere with the conformational transition during the initiation of RNA synthesis  
[105]. In fact,  besides the active site, the X­ray derived co­crystal structures of compounds bound to NS5B 
revealed  distinct   allosteric   regulatory   sites   that   are   located  distant   to   the   active   site   and  are   targets   for  
developing antiviral  agents.  Accordingly,  compounds   that   interact  either  with   the RdRp active  site  or   the 























IDX375 Polymerase Inhibitor Idenix Phase I
ABT­072 Polymerase Inhibitor Abbott Phase I
MK­3281 Polymerase Inhibitor Merck Phase I
PSI­7851 Polymerase Inhibitor Pharmasset Phase I
ABT­333 Polymerase Inhibitor Abbott Phase I






RG7128 Polymerase Inhibitor Pharmasset/Genentech Phase I
VX­222 Polymerase Inhibitor Vertex Phase II




GS 9190 Polymerase Inhibitor Gilead Phase II
VX­759 Polymerase Inhibitor Vertex Phase II




Several   classes  of   structurally  distinct  NNIs  of   the  HCV  RdRp  have  been   identified   and  disclosed;   these 














containing   heterocycles,   by   extending   the   original   derivatives   to   topologically   related   scaffolds   and 
















Thiophene   and   Benzimidazole   derivatives.   Cross­resistance   studies   and   synergistic   inhibition   of   HCV 
polymerase, by combination of a Benzimidazole and a Benzothiadiazine, further confirmed that these two 
structurally distinct classes of inhibitors had non­overlapping binding sites and thus acted with different mode 
of  action.  Heterocyclic Benzo­1,2,4­thiadiazine derivatives are specific  inhibitors  of RNA synthesis   in HCV 
replicon   systems   [107].   GlaxoSmithKline   (formerly   SmithKline   Beecham)   disclosed   a   novel   class   of 
Benzothiadiazine   derivatives,   from  which   a   representative   compound   displayed   good   potency   both   in 























least   eight   antiviral   drugs   in   clinical   development.  The  disappointments   are  not   new:   drugs   specifically 
targeting the hepatitis C virus have been in the works since the early 1990s, but no compound of this kind has  
yet   advanced   to   phase   3   trials.  Four   of   the   failed   drugs   were   inhibitors   of   NS5B   RNA   polymerase. 




that   are   known   to   have   entered   clinical   trials,   several   other  NNIs   of  HCV   are   in   advanced   preclinical  
development and early results for the newer polymerase inhibitors look promising. A series of  , ­diketoacidα γ  
compounds, as inhibitor of HCV polymerase, has been identified. Further optimization led to identification of  
a   potent  HCV  NS5B  polymerase   inhibitor,  with   an   EC50  of   45  nM.  Compounds   of   dihydroxypyrimidine 
carboxylic   acid   class   are  believed   to   chelate   the   two   catalytic  Mg2+  ions   in   the   active   site   as  diketoacid 
compounds. However, no data of in vivo activity for the pyrophosphate mimics are available and the high ionic 
nature of these compounds may raise concerns, such as low bioavailability and toxicity. The binding sites for 
(2s)­2­[(2,4­dichloro­benzoyl)­(3­trifluoromethylbenzyl)­amino]­3­phenyl­propionic   acid   and   (2s)­2­[(5­
Benzofuran­2­ylthiophen­2­ylmethyl)­(2,4­dichlorobenzoyl)­amino]­3­phenylpropionic   acid   are   located   in 
the   thumb   subdomain   35  Å   far   from   the   active   site.   A   benzimidazole   inhibitor   and  N,N  disubstituted 
phenylalanine inhibitor also induced an allosteric interaction[108]. There are 3 classes of inhibitors that bind  
to   a   pocket   in   the   thumb  domain.   Phene   2­carboxylic   acids,   phenylalanine  derivatives   and   cyclopentyl  






be useful  as  anticoagulant,  antibacterial,  anti­inflammatory,  anticancer and anti­HIV agents.  Very  few are 
reported   to   be   able   to   counteract   HCV.   Only   some   coumarin   derivatives   like   Osthole   (7­methoxy­8­
prenylcoumarin) is capable of inhibiting HCV replication and/or proliferation. In particular, Osthole is able to  
counteract the progression of hepatitis C into hepatocarcinoma.  Since the great variability of pharmacological 
response   of   coumarins   is   connected   to   large  modification  of   their   substituents,  Mazzei   and   co­workers 
(Department   of   Pharmaceutical   Sciences,  Genova,   Italy)   found   interesting   to   synthesize   some   coumarin 
Mannich bases in order to examine their ability to inhibit HCV replication.  This idea proved to be a winning 






In  a   journey  of  25  years,  HIV­1,   the   retrovirus   responsible   for   the  acquired  immunodeﬁciency  syndrome 
(AIDS), has gone from being an “inherently untreatable” infectious agent to one eminently susceptible to a  






National   Cancer   Institute   together   with   collaborators   from   Burroughs­Welcome   company,   identified   3­
azidothymidine (AZT,zidovudine ) as the first nucleoside inhibitor with in vitro anti­HIV activity.
The discovery of the anti­HIV activity of AZT was a landmark in the development of antivirals, providing the 
first   proof   of   concept   that   the   replication   of   HIV   could   be   controlled   by   chemotherapy   and   thereby 
establishing   the   foundation   of   antiretroviral   drug   discovery   research   [123].  Thus,   AZT   became   the   first  
nucleoside HIV reverse transcriptase inhibitor (NRTI).  Over the course of  25 years that followed after  this 





Members  of   the  of  NRTIs  were   eventually   joined  by  nonnucleoside  RT   inhibitors   (NNRTIs),  which  were  
discovered in 1990, and interact with an allosteric binding site on HIV­1 reverse transcriptase that becomes 
exposed  upon  ligand  binding[124].  NNRTIs  are  a  key  part  of   typical  HAART  regimes   for   treatment­naive  















1/AIDS   is   both   cause   and   consequence.  Many   challenges   remain,   including  1)   the   life­long  duration  of 
therapy; 2) the ultimate role of pre­exposure prophylaxis (PrEP); 3) the cardiometabolic side­effects or other  
toxicities   of   long­term   therapy;   4)   the   emergence   of   drug­resistance   and   viral   genetic   diversity   (non­B 
subtypes); 5) the specter of new cross­species transmissions from established retroviral reservoirs in apes and 
Old World monkeys; and 6) the continued pace of new HIV­1 infections in many parts of the world. All of these  
factors  make   refining   current   therapies   and   developing   new   therapeutic   paradigms   essential   priorities.  
Fortunately, there are exciting new insights into the biology of HIV­1, its interaction with cellular resistance  
factors,  and  novel  points  of  attack   for   future   therapies.  The  current  science  will   lead   to  new therapeutic 
strategies with far­reaching implications in the HIV­1/AIDS pandemic. 
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M E T H O D S
1.1 docking
Molecular docking is a multidimensional optimization problem,
requiring efficient samplaing across the entire space of positional,
orientational, and confermational possibilities available to both
a receptor and a ligand it recognizes. Recent flexible docking
studies and the results from the docking section of the critical
assessment of protein.Structure (CASP2) prediction contest [14]
suggest that a suitable combination of homology modeling, dock-
ing strategies and experimental studies can be used to reliably
predict protein-ligand structures.
Protein-ligand interactions, described by the induced-fit model
of molecular recognition, involve structural alterations in the
receptor binding site and the ligand. Thus, it is critical that the
model allows for flexibility in both the ligand and the receptor.
The compouter programs AUTODOCK, GOLD, GLIDE, FLEX
etc, which we have now integrated into our studies of protein-
ligand interactions, allow partial flexibility of the receptor and
full flexibility of the ligand . flexibility of the ligand and recep-
tor is computationally cumbersome to include in the docking
simulations.If the ligand and the receptor are completly flexible
during the simulation, even if we exclude everything else but
the receptor binding site, the computational cost of the docking
problem becomes so great. Proper ways to accomodate flexibility
in the docking simulations without increasing the computational
effort too much is one of the most important issues in the de-
velopment of new metodologies at the moment.Computer-aided
ligand-receptor docking has become an important research tool
in structural biology.
1.1.1 Autodock
AUTODOCK (current version 3.0 and 4.0) docks flexible small
moleculae ligand to rigid macromolecular recepor and with some
residue flexibility of receptor. In the docking simulations the
number of rorsional degrees of freedom in the ligand can be
varied, but some angles and bond distances are maintained rigid.
AUTODOCK uses Monte-Carlo simulated annealing and/or
Lamarckin genetic algorithm minimization scheme combined
with a rapid, atomic resolution, grid based method of energy
evaluation utilizing the Amber force field. In order to find low
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energy confermations of ligands in the receptor binding site.The
overall interaction energy between chemical species (i.e between
atoms of the ligand and the receptor) is estimated by consider-
ing both Lennard-Jones atom-atom potential and electrostatic
effects, summed for the individual interactions between atoms. A
distance-dependent dielectric constant or special solvation energy
grid can be used to account for the solvent effects.
Stoddard and Koshland were pioneering users of AUTODOCK
in a clever prediction of a structure of a peotein-protein com-
plex by docking seprate domains. apartm from many uses of
AUTODOCK in various ways of protein ligand interaction, it also
helped in invention of a drug which is in clinical trials for HIV.
McComman et al in 2007 used AUTODOCK in conjunction with
the Relaxed Complex Method. Merck Pharmaceutical company
used McCommon’s et al group protocol of AUTODOCK to de-
sign new drugs that target integrase, which lead in October 2007
to the first clinically approved HIV Integrase inhibitor:Isentress.
The docking of the ligands was explored with AUTODOCK
and the docking energy produced with the AUTODOCK force
field was corrected with the energy needed to solvate the ligands
1.1.2 Protocol
Autodock 4 was used for all docking calculations(Morris GM
et al journal of computational chemistry; 2009). The AutoDock-
Tools(ADT) package was employed to generate the docking files
and analyze the docking results. In the abscence of literature data
for the binding of different class of compounds, we performed
molecular docking taking carben alpha atom. of the respective
resistant mutant of the corresponding site as in case of HCV and
the resistant mutation isolated from our lab in case of BVDV, as
a grid center, for each compounds. The interaction pattern and
key residues of crystallized ligand (table1), which correspond to
the binding site A, B, C, and D were used for the identification of
proper orientation of our compounds into the different binding
sites. Two different grid boxes, one for each binding site, were
centered on the average mass center of the ligands. Thus, a grid
box of 91 X 91 X 86 points and a grid spacing of 0.375Å was set
in order to accommodate the NNIs that bind on to the different
sites of NS5B polymerase.
The second grid box (spacing,0.375Å) of 62 X 75 X 75 points
was implemented in such a way to accommodate the NNIs into
the more buried area of NS5B. The grid maps were generated
for each atom probe, describing its interactions with the com-
pounds. Autogrid 4, as implemented in the Autodock software
package, was used to generate grid maps. The Lamarckian ge-
netic algorithm (LGA)62 was employed to generate orientations
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or conformations of the ligands within the binding site. The
global optimization started with a population of 150 randomly
positioned individuals, a maximum of 2.5 X 108 energy evalua-
tions, and a maximum of 27,000000 generations, as mentioned
the protocol for blind docking. A total of 200 runs was performed,
while all the remaining run parameters were maintained at their
default settings. A cluster analysis was carried out using 2Å as
the root-mean-square deviation tolerance. Docking experiments
were also tried using a single grid box comprising the two bind-
ing sites. Although Autodock performed quite well in selectively
positioning the ligands in the right pockets, the results in term of
root-mean-square-deviation (rmsd) values were not fully satisfy-
ing. This is likely due to the fact that with only 100 runs such a
large region is not sufficiently explored. Nevertheless, a higher
number of conformation sampling, may not assured better results
in the absence of required no. of runs. So we went for 200 runs
although it was computationally demanding.
1.2 assessment of docking
1.2.1 Redocking
. Further refinement of docking was performed, aiming to check
out the more realistically binding mode conformations of com-
pounds with no experimental data. In order to check for the
reliability of the docking protocol, we performed docking studies
on NS5B polymerase complexes. The docking results were eval-
uated through a comparison of the predicted docked positions
of the ligand and the experimental ones. As a measure of dock-
ing reliability, the rmsd between the positions of heavy atoms
of the ligand in the calculated and experimental structures was
considered.
The choice of the best conformation was based on the assump-
tion that, although for high-throughput screening protocols, only
the first ranked conformations should be considered (that is, the
conformer characterized by the lowest estimated free energy of
binding)63. In other cases, the lowest energy conformer of the
most populated cluster should also be taken into account64. We
applied the second protocol for investigation of binding mode
of newly identified potent lead of different class of compounds.
While the best docked is the lowest energy docked conformations
of the first autodock generated cluster.the best cluster is the low-
est energy docked conformation of the most populated cluster
and best fitted cluster is the lowest energy docked confermation
of the cluster showing the lowest rmsd value.In the ideal case, i.e.,
the error free docking program, the three conformations would
have coincided.
51
The fact that Autodock reproduces the correct conformations
(best fitted cluster) by 100 percent reflects the intrinsic lack of
accuracy (at least for NS5B) of the implemented scoring function
in selecting the right pose, and this is at the basis for the further
analysis using molecular dynamics.
Flexibility of the ligand and the receptor is
1.3 molecular dynamics
Molecular Dynamics (MD) simulation is a technique founded
upon the basic principles of classical mechanics that provide a
dynamical picture of the individual particles of the system at a
microscopic level. Using this technique successive configuration
of the molecular system (in the phase space of coordinates and
momenta) is generated by integrating Newton’s law of motion.
The result is a trajectory, which contains the microscopic time
evolution of the system in the phase space [? ? ]. From the trajec-
tory generated, one can compute the dynamical properties such
as absorption spectra, rate constants and transport properties.
Further, on combining MD with statistical mechanics as a mean
of sampling, one can compute equilibrium properties such as
average thermodynamics quantities, structure, and free energies
along the reaction path seen as a union of all possible states of
the system [? ? ]. For instance, the statistical ensemble average of





The assumption made here is called the ergodic hypothesis, i.e
given an infinite amount of time, ensemble average of observable
A, is equivalent to its time average. The main aspect in atomistic
MD simulations are:
• An algorithm that samples the phase space
• The choice of the interaction potential, V(r), between the
atoms of the system.
Several simulations approaches were developed in the last
decades that differs in the method to sample the phase space.
The most fundamental form used to describe equation of motion









) = 0 (1.2)
where L(q,q˙) is Lagrangian defined as the difference between
the kinetic and potential energies L=K-V, where qj are general-
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ized coordinates and q˙j are the associated time derivative. The





On substitution with the usual definition of kinetic and poten-
tial terms with cartesian coordinates ri, equation 1.2 becomes:




where V(r), the potential, is a function of the atoms positions
and Fi represents the total force on atom i. In this equation one
assumes that the nuclear motion of constituent particles obeys
the laws of classical mechanics. This is an excellent approxima-
tion if the distance in the energetic (translational, rotational and
vibrational) levels of the involved degrees of freedom is << kT ,
where k is the Boltzmann constant and T the temperature.
In the Hamiltonian form the equation of motion for the carte-








1.3.1 Integration of Newton equations of Motion
Under the influence of a potential, the motions of atoms are
strongly coupled to each other giving rise to many-body prob-
lems that cannot be solved analytically [? ]. Therefore, in MD
calculation an iterative numerical procedure is employed to ob-
tain an approximate solution for the equations of motion.
The two important properties of the equations of motion to be
noted are:
• They must be time reversibe (t=-t).
• Conservation of total Energy (Hamiltonian) of the system.
For the first point, as the Newton equations are time reversible
also the algorithm used is supposed to satisfy the same time
reversal symmetry. The algorithms that are not time reversible do
not normally preserve the phase space volume, i.e. they do not
satisfy the Liouville theorem. For the second point, conservation
of Hamiltonian is equivalent to conservation of total energy of
the system and provides an important link between MD and
statistical mechanics. The energy conservation condition H(p,r) =
E, defines a hypersurface in the phase space called the constant
energy, imposing a restriction on system to remain on this surface
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[? ]. A good way to check the accuracy of the algorithm is to
follow the temporal evolution of an observable A that should be
conserved (e.g. the total energy). In general a good algorithm
must be such that:
| A(tn) −A(t0) |
〈A(t)〉  1, for (tn − t0) ∆t (1.6)
there is no drift in the total energy.
The MD integration of the Newton’s equation which have a con-
tinuous form, are based on assumption that position, velocities
and other dynamical properties can be discretized using the
Taylor series expansion:






∆t3b(t) + .... (1.7)






∆t3c(t) + .... (1.8)
The choice of the integration method depends on the degree of
accuracy of problem at hand. One of the most useful form used
is the velocity verlet algorithm [? ], a variant of verlet algorithm
[? ]. The advantage is using velocity verlet method is that posi-
tions, velocities and acceleration are well synchronized that allow
to calculate the kinetic energy contribution to the total energy
at same time, from which potential energy is determined. The
equations are:








where ai,ri,vi are respectively the acceleration on the atom i,
the atom position and the atom velocity. The algorithm has an
accuracy of O (∆t3) for the variables and it is reversible in time.
Together with conservation of energy and time-reversibility
another important feature of an integrating algorithm is to permit
long time steps ∆t. It is expected that the numerical Newtonian
trajectory will diverge from the “true” Newtonian trajectory. How-
ever, it is important that the integrating algorithm maintains a
well defined energy tolerance ∆E throughout the simulation time.
The error (∆E) is known to decrease on decreasing the time step
∆t. The aim here is to find a balance between using the largest
possible time step and maintaining an acceptable ∆E all along
the simulation. A large time step would lead to faster exploration,
but energy would fluctuate widely with the possibility of the
54
simulation being catastrophically unstable, on other hand too
short time step would lead to computation being needlessly slow.
The choice of an integration step is determined by the nature of
forces acting on the system. The golden rule is to choose time
step (∆t ∼ 10−15s) such that the fastest motion of the system
can be integrated accurately. This requirement is a severe restric-
tion, particularly as high frequency motions are relatively of less
interest and have minimal effect on the overall behavior of the
system. One suggested approach is to freeze out such vibrations
by constraining the appropriate bonds to their equilibrium values.
Details of this approach is discussed in subsection 1.3.4, or to
use multiple time step approach which is discussed in subsection
1.3.2.
1.3.2 Multiple Time Step Integrator
One of the approaches to accelerate the integration of equations
of motion, is to use “multi-time” step algorithm such as reverse
reference system propagation algorithm (r-RESPA)[? ]. In the
algorithm (r-RESPA), the molecular system is classified into num-
ber of groups according to how rapidly the forces varies over
time. The starting point is the Liouville operator formulation,
which can cast the equations for the Hamiltonian system (see
equation1.5) in a general form:
x˙ = iLx (1.11)
where x is the phase vector and iL is the Liouville operator.
Consider a molecular system containing N atoms (or 3N degrees
of freedom) with x = {ri,pi} representing a point in the phase
space. The Liouville operator in cartesian coordinates is defined
as:















On subsituting equation 1.5 into equation 1.12, we get:












where Fi is the force on ith degree of freedom, and {...,...} is the
poisson bracket. The classical time propagator U(t) is unitary and
defined as eiLT , and the evolution of system Eq. 1.11 is expressed
as:
x(t) = eiLtx(0) (1.14)
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The action of operator U(t) on x(0) cannot be determined ana-
lytically, however the operator can be decomposed using Trotter
theorem, such that the action of U(t) on x(0)for each part can be


















where ∆t=t/P. For finite P, the numerical iteration procedure
is accurate to the second order in the time step at long times.
From equation 1.15, for the three exponential terms, we define












2 ) +O(t∆t2) (1.16)
Since the three exponential terms in G ∆t are separately unitary,
G (∆t) is also unitary i.e G−1(t) = G†(t) = G(-t). Lets us now














The operator U1(∆t2 ) becomes a translation operator on the
positions: ri → ri + ∆t( pimi ), and operator U2(∆t) becomes a
translational operator of momenta: pi → pi + (∆t2 )Fi(r). On com-
bining these two facts to action of operators in equation 1.16 on
complete set of positions and momenta, yields the approximate
evolution:




vi(∆t) = vi(0) +
∆t
2mi
[Fi(0) + Fi(∆t)] (1.18)
which is the famous velocity verlet [? ] integrator derived
using the operator formulation. The power of the operator based
approach is its symplectic property which ensures no drift in
the total energy, resistance to increase in time steps and allows
generating stable long trajectories.
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r-RESPA algorithms have been successfully employed to in-
corporate motions on more than two time scales. Let us con-
sider a system with three characteristics time scales, a refer-









i . We define their Liouville operators as iL
ref,
iL(del) and iL(Del) and the corresponding timescales δt, ∆t and




































Thus, the correction due to slowest time scale is applied every
m×n timesteps, and the intermediate time scale correction is
applied every n steps. Such numerical procedure lead to consid-
erable saving in the CPU time to perform a MD simulation.
1.3.3 The interaction potential
Figure 1: force field
The potential function V(r) from which the forces used in MD
are derived depends on the atomic coordinates ri.
V(r) used in this thesis has the following expression:
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The first two terms (two and three body interactions respec-
tively) represent the bonds and angles potentials, that are ap-
proximated by harmonic functions. The third and fourth term
describe four body interactions. Improper dihedral terms are
typically described by an harmonic function. Instead proper di-
hedrals are described by periodic functions (i.e. cosine functions)
of a given periodicity n. The last two terms are a Lennard-Jones
(LJ) potential and a coulomb potential between pair (ij) of atoms.
The LJ terms reproduce the Van der Walls interactions, while the
coulomb potential terms reproduce the electrostatic properties
of a protein. These interaction are modelled using the two-body
approximation which doesnot explicitly account for the polar-
ization effects, but on a average. The parameters used in this
kind of potentials are typically obtained from quantum chemical
calculations and experimental data (e.g. crystallographic data,
spectroscopic data, etc). Among the popular sets of parameters
(force fields) for MD simulations of proteins we can cite for ex-
ample AMBER, GROMOS, CHARMM and OPLS. They all use
the potential function expression given above for all the atoms of
the simulated system except for the GROMOS(and CHARMM19
force field) force field in which a united atom description is used
for non-polar hydrogens.
In MD simulations the description of the solvent (water for
most of the biologically interesting systems) can be explicit or
implicit. In the first case solvent molecules with a full atomistic
force field description are added in the simulation box at the ex-
perimental density. In the implicit solvent description the solvent
is treated as a dielectric medium in which the system is embed-
ded. This is clearly a more approximated description but it is
also computationally much more efficient since in many practical
cases the solvent constitutes the majority of the atoms. In this
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thesis we used for all the MD simulations the AMBER-95 and
AMBER03 force field with an explicit description of the solvent
given by the TIP3P[? ] water model.
1.3.4 Constraints for Hydrogen
Constraints are used in MD to fix bonds to their equilibrium value.
This allows increasing the simulation time step ∆t. Constraining
the bond lenght does not alter significantly the statistics as these
are quantum degrees of freedom being mostly in their ground
state at the normal simulation temperature. Using the bonds
constraints it is possible to use ∆t ∼ 2fs [? ] (2-4 times larger than
the one that can be used without constraints). A common method
to introduce constraints is the algorithm SHAKE [? ], in which
after each time step the atoms positions iteratively are modified
in order to satisfy the constraint.
SHAKE may have convergence problems when applied to large
planar groups and its implementation could hinder the efficiency
of computing. To improve these aspects the LINCS algorithm was
recently introduced. For water molecules it is also possible to use
an analytic solution of SHAKE called SETTLE.
1.3.5 Boundary conditions
To simulate a finite size system, boundary conditions are needed
to avoid artifacts near the border of the simulation box. Typically
periodic boundary conditions (PBC) are used. In this scheme
short range non bonded interactions are calculated using the
minimal image convention (only the nearest replica is considered).
Typically a cut-off radius (Rc) is used for LJ interactions of the
order of 10 Å. To avoid interactions between a particle and its
periodic image each box side must be larger than 2Rc.
The coulomb energy is instead treated considering the full pe-
riodicity of the system. For a periodic lattice made by N particles














where n indicates the periodic images, i,j the particles and the
symbol ? indicates that the summation does not contain the term
with i = j if n = 0.
The periodicity of the system speeds up the evaluation of the
coulombic term. Although convenient, effective, and simple to
apply, certain subtle problems arise for long range forces (electro-
statics), whose spatial range may extend beyond the boundaries
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of the container into surrounding images, present a challenge.
Long range forces can only be correctly calculated by summing
over all the periodic replicas of the original system. However,
the associated computational effort is considerable. Fortunately,
methods have been developed to treat this problem. Specifically,
the Ewald summation technique, developed originally to treat
Coulomb interactions and later extended to treat general interac-
tions of the form
1
rn
for n6 3 has proved enormously successful.
The basic idea behind the technique is to divide the relevant part
of the potential into a short range and a long range contribution.











where erf(x) and erfc(x) are the error function and complemen-
tary error function, respectively (erf(x) + erfc(x)= 1). The variable,
R, is a convergence parameter, which can be optimized for each
system studied. The short range term, erfc(αr)/r, is treated as
an ordinary short range interaction, i.e., using a spherical cutoff
to truncate the interaction at large spatial distances where the
potential is small. The long range term, erf(αr)/r, is Fourier trans-
formed into reciprocal space, where it takes the short-ranged
form, exp(-g2/4α2), and can be evaluated accurately by sum-
ming over only a small number of reciprocal space vectors of
the simulation cell. Such reciprocal space sums can be evaluated
with high a degree of efficiency (N log N) using particle-mesh
methods(PME)[? ]. An extension of PME is the smooth PME.
With respect to PME, this method uses a fixed cuttoff in the
direct sum and uses the B-spline interpolation of the reciprocal
space structures onto a rectangular grid, permitting the use of
fast Fourier transforms to efficiently calculate the reciprocal sum.
In this thesis we use SPME method to evaluate the electrostatic
energies[? ].
1.3.6 Statistical Ensembles
Molecular dynamics can be performed in different statistical en-
sembles. The traditionally used ensemble to perform MD is the
micro-canonical ensemble (NVE), where the number of particles
(N), the volume (V), and the total-energy (E) of the system are
fixed to a constant value.
The simple extension of NVE ensemble is the canonical one
(NVT), where the number of particles, the volume and the tem-
perature are fixed to a constant value. The temperature T, in
contrast to the number of particles N and volume V, is an inten-
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sive parameter. The temperature T is related to the time average















where, Ekin is the kinetic energy, kB is the Boltzmann constant.
The simplest way to control the temperature, is to rescale the




, where Tcurr is
the current temperature calculated from the kinetic energy and
Treq is the desired temperature (for instance 300 K). However,
an alternative way to maintain is to couple the system to an
external heat bath that is fixed at the desired temperature. The
bath acts as a source of thermal energy, supplying or removing
heat from the system as appropriate. This thermostat is named
as the “Berendsen” thermostat. It is extremely efficient for re-
laxing a system to the target temperature, but once the system
has reached equilibrium, it might be more important to probe a
correct canonical ensemble.
Extended system methods, was originally introduced for perform-
ing constant MD simulation by Nosè in 1984, and subsequently
developed by Hoover in 1985. The idea of the method was to
reduce the effect of an external system, acting as a heat reservoir,
to an additional degree of freedom s. This reservoir has a po-
tential energy (f+1)kBTln s, where f is the number of degrees of
freedom in the physical system and T is the desired temperature.








Q is considered as the fictitious mass of the extra degree of free-
dom. The magnitude of Q determines the coupling between the
reservoir and the real system and so influences the temperature
fluctuation. If Q is large then the energy flow is slow; in the
limit of infinite Q, conventional molecular dynamics is regained.
However, if Q is small then the energy oscillates, resulting in
equilibrium problems. It has been suggested that Q should be
proportional to fkBT.
Another ensemble we discuss here it the NPT ensemble, an ex-
tension of NVT ensemble, where together with temperature the
pressure of the system is maintained to a constant vaue. As most
experimental measurements are usually made under conditions,
which include a fixed pressure P, temperature T, and number
of atoms N (constant-NPT ensemble), and so simulations in the
isothermal-isobaric ensemble are the most directly relevant to
experimental data. A simulation in NPT ensemble maintains the
constant pressure by changing the volume of the simulation cell.
61











An alternative to maintain constant pressure is to couple the
system to a “pressure“ bath, analogous to the temperature bath.






(Pbath − P(t)) (1.25)
where τp is the coupling constant, Pbath is the pressure of the
’bath’, and P(t) is the actual pressure at time t. The volume of
the simulation box is scaled by a factor λ, which is equivalent to
scaling the atomic coordinates by a factor λ1/3. Thus:




and the new position are given by:
ri
new = λ1/3ri (1.27)
In the extended pressure-coupling systems, an extra degree
of freedom, corresponding to the volume of the box, is added
to the system. The kinetic energy associated with this degree
of freedom (which can be considered to be equivalent to piston







), where Q is the ’mass’ of
the piston. The piston also has a potential energy PV, where P
is the desired pressure and V is the volume of the system. The
volume varies in the simulation with the average volume being
determined by the balance between the internal pressure of the
system and the desired external pressure. In this thesis, we have
performed MD simulation in both NVT and NPT ensembles.
1.3.7 Solvation effect
In most cases, we are interested in the properties of molecules
in solution, usually in aqueous solution. therefore, it is essen-
tial to calculate not only the interaction between the atoms of
biomolecules, but also the solvent effect on the interaction. there
are two different approches to include the solvent effects in molec-
ular dynamics. One is explicit solvent model, the other one is
the continuum solvent model, also known as the implicit solvent
model.
In explicit solvent models we need to calculate the interaction
between the particles and every solvent molecule individully,
therefore it is a very “computationally expensive ” job, and the
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cost increase with the number of interaction sites in the water
model. Algorithms such as Particle Mesh Ewald (PME) method,
particle-particle/particle-mesh(P3M) method are developed to
accelrate the simulations.
Even with advanced algorithms, one obvious drawback of the
explicit solvent model is the large system size due to numerous
solvent molecules. An alternative approch is using the contin-
uum solvent models, such as the Generalized Born(GB) model.
This model represents the solvent implicity as a continuum with
dielectric properties of water, and also includes the charge screen-
ing effects of salt. this lowers the calculation expense in two
aspects: first, it removes the calculation of the interactions and
motions involving solvent molecules;second, the absence of sol-
vent friction accelerates the dynamics of the solute. However, the
computing cost of GB model scales up with the size of the system.
for large systems, the computing cost may be greater than using
explicit solvent model.
Both explicit solvent and implicit solvent models have cer-
tain strengths and weakness. Calculations using explicit solvent
generally yield more accurate results. In some cases, such as
simulations involving water bridges, explicit water molecules are
essential for the calculation. However, systems using explicit sol-
vent have many more atoms (in most case mostly water molecules
), demanding additional computing resources. Due to the fraction
force from water molecules, the dynamics of the solute is also
slower in the explicit solvent. this may be useful for understand-
ing the real time scale of a biological event. However, for some
studies where rate is not a factor, but the results of the motion
are important, the implicit solvent model will be more efficient.
Another important advantage of implict solvent model is that it
calculates solvent free energy, instead of energy. In the explicit sol-
vent model, water atoms are considered to be part of the system,
and solvent-solute interactions are included in the non-bonded
calculations. There is no independent solvation term. In implicit
solvent the simulated system only includes solute. the molec-
ular mechanic interactions are calculated first in vacuum. then
an additional term, the solvation free energy is calculated and
included in the energy of the system. the implicit solvent mimics
the average effects of the water molecules, therefore it genrates
solvation free energies. it is essentail for methods such as Molec-
ular Mechanics-Poisson Boltzmann (Generalized Born) Surface
Aea (MM-PB(GB)SA) approch, which needs an explicit solvation
free energy term in calculation. just a note, MM-PB(GB)SA is a
post-processing analysis, which means it is still recommended
to genrate the structures using explicit solvent first, then using
implicit solvent model to analyze the solvation free energy on
existing structures.
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1.4 long time scale simulations
Molecular Dynamics (MD) simulations allow investigating pro-
cesses occurring on timescales of ∼100ns. However, most interest-
ing and relevant biological process happen on time scales that
are orders of magnitude larger, and are therefore termed as rare
events. For example, protein folding (µs-few seconds), protein-
protein interactions, transport of molecules across membrane
channels (order ∼ µs) and many others. Over the years, we have
observed an astounding increase in computer power (Blue gene,
DESRES), which promise to increase utility of MD simulations
to investigate more and more complex systems on µs timescale.
However, these supercomputing machines are not available to all
the research groups. Therefore another approach to overcome the
timescale problem is to renounce the all atom approach and to
use coarse grained models. This would retain the essential char-
acteristics, however you require a detailed knowledge of system,
that is often not available.
For systems, where its important to maintain the atomistic de-
scription, one can exploit methodology aimed at accelerating
rare events to timescales reachable in MD simulations. Notable
success has been achieved is using the accelerating methodol-
ogy in diverse fields of interest. From their scope and range of
applicability, they are classified in four categories [? ]:
1. Methods aimed at improving sampling, in a subspace of few
predefined collective variables (CVs), that allow reconstruct-
ing the probability distributions as a function of chosen
CVs. Examples of these methods include thermodynamic
integration [? ? ], free energy perturbation [? ], umbrella
sampling [? ], conformational flooding [? ], weighted his-
togram [? ? ? ], steered MD [? ], Jarzynski’s identity based
methods [? ] and adaptive force bias [? ]. The power of these
methods in highly dependent on judicious choice of CVs,
and computational performance degrades as a function of
the number of variables.
2. Methods aimed at exploring the transition mechanism. Ex-
amples in these catogeries are transition path sampling[?
? ], finite temperature string method [? ? ], transition in-
terface sampling [? ] and forward flux methods [? ]. These
methods do not require in most cases, an explicit definition
of a reaction co-ordinate, but require a priori knowledge of
initial and final states of process under investigation.
3. Methods for exploring the potential energy surfaces and
localizing the saddle points that corresponds to a transition
state. Examples in these catogeries are dimer method [? ],
hyperdynamics [? ], multiple time scale accelerated MD [? ]
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and event based relaxation [? ]. The power of these methods
is limited to low dimensionality, and reliability degrades
with the complexity of system.
4. Methods in which the phase space is explored simulta-
neously at different values of temperatures, are parallel
tempering [? ] and replica exchange [? ], or as a function of
the potential energy, such as multicanonical MD [? ] and
Wang-Landau [? ].
1.4.1 Metadynamics
Metadynamics method encompasses several features of tech-
niques mentioned earlier and provides a unified frame work
for computing free energies and accelerating rare events. It is
a powerful algorithm, based on dimensional reduction that is
used for accelerating rare events in system described by com-
plex Hamiltonians, at a classical or quantum level [? ]. Before to
use the algorithm, the requirements are to identify a set of CVs,
which are assumed to describe well the process of our interest.
The power of the algothim lies in treating the CVs simultaneously
and in its flexibility: the method can be proficientely used both
for reconstructing free energy and for accelerating rare events.
1.4.2 The algorithm
Consider a system described by a set of co-ordinates x and a
potential V(x) evolving under the action of molecular dynamics,




). Since our interest is to describe the system using a set of
CVs, Sα(x), α=1,d where d is a small number assuming they
provide a good coarse-grained description [? ]. The equilibrium

















where s denotes the d dimensional vector (s1,....,sd), with the free
energy given by:












in equation 1.29, capital S is used for representing the function of
the coordinates S(x), while lower case s is used for denoting the
value of the CVs.
Consider now a trajectory x(t) of the system at temperature T.
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On computing the trajectory for a very long time, probability
P(s) can be obtained by taking the histogram of CV s along
this trajectory. At time t, P(s) ∼ 1t
t∫
0
dt ′δ (S(x(t’) - s). If the system
displays metastability, the motion of s will be bound in some local
minimum of F(s) (i.e., in local maximum of P(s)), and will escape
from this minimum with a very low probability on the timescale
determined by the potential V(x) alone. In Metadynamics, the
metastability is eliminated by modifying the underlying potential
V(x), by adding a history dependent term consisting of Gaussians
centered along the trajectory in s space during the evolution of
the system [? ? ]. Each time a new gaussian is added at time τG,
the biasing potential at time t is given as:





(S(x) − s(t ′))2
2δs2
) (1.30)
In equation 1.30 capital S is used for denoting the function of
the co-ordinates S(x), while lower case s is used for denoting the
value of the CVs, s(t)=S(x(t)) is the value taken by the CV at time
t, ω is gaussian width, δs is the gaussian width and frequency τG
at which gaussians are added. The basic assumption of metady-
namics is that VG(s,t) defined in equation 1.30 after a sufficiently
long time provides an estimate of the underlying free energy:
lim
t→∞VG(s, t) ∼ −F(s). (1.31)
Here, in equation 1.31, a equilibrium quantity free energy (F(s))
is estimated by a non-equilibrium dynamics. Equation(1.31) can
be qualitatively understood as slow ’deposition’ (i.e. ω→ 0), and
in this limit VG(s,t) varies very slowly, with the probability to




(s,t))]. If the function F(s)+VG(s,t) has some local minimum, s will
be preferentially localized in the of this minimum and Gaussians
will be deposited, till the minimum is filled. If we consider the
situation where F(s) ∼ −VG(s,t) in a region Ω(s). In this case
the probability distribution would be flat and the locations of
the gaussians will not be affected by the bias. Hence, if ω →
0, only corrugations in the free energy that are not flattened by
the dynamics will be the order of the size of the newly added
gaussians.
In most cases, it is not sufficient to describe the process of interest
using a single CV, therefore in cases where we use more than one
CV at the same time, the metadynamics potential is given by















and it is necessary to choose metavariable δsα for each CV. The
time required to escape from a local minimum is determined by
number of Gaussians needed to fill the basin. This number is
proportional to (δsα)d where d is the number of CV chosen to
describe the system. The efficiency of the method scales exponen-
tially with number of CV. The added gaussians can reproduce
features of the FES on a scale larger than δs. The quality and
accuracy of the free energy construction is highly influenced by
the parameters of metadynamics. The parameters need to be
chosen wisely, striking a balance between accuracy and efficiency.
1.4.3 How to Choose CVs
Reliability of Metadynamics is highly dependent on the choice
of CVs, and this in turn depends on the process of investigation.
Therefore if not essential it is important to have good knowledge
of the process under investigation, which aids in chosing the
right CVs. Important features that CVs must satisfy are:
1. They should be slow variables able to describe well the
process of interest.
2. They should be able to distinguish between the initial, in-
termediate and final states.
Practical Example of choosing CVs
For example, lets consider the diffusion of antibiotics through
OmpF channel. The OmpF channel has an axis of symmetry
along Z-axis, with a hourglass shape. Here we want to follow the
exit of antibiotic from the channel. In this case, one appropriate
CV would be distance: defined as difference between the center
of mass (com) of the antibiotic (a1) and the center of mass of











We make a assumption in equation 1.33, com of OmpF (p1) is
constant respect to com of the antibiotic(a1). Therefore using
this CV sdist we caputure the location of antibiotic in the OmpF
channel.
1.4.4 Estimation of Error
Error estimation in Free energy calculations is very much depen-
dent on the meta variables (ω, δs, τG). In [? ] it has been shown
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that the error on reconstruction profile is determined by the ratio
of (ω/τG) and not by ω and τG alone. For instance, adding Gaus-
sian of height ω=1.0 Kcal mol−1 every τG = 4ps, is equivalent to
adding Gaussian of height ω=0.5 Kcal mol−1 every τG = 2 ps,
with a requirement that τG remains much shorter than the time
required to fill the free energy basin. The error  in metadynamics
is a measure of expected deviation of VG(s,t) from -F(s):
ε2 (s) =
〈











Remarkably, the error does not depend on F (s). An alternative
expression for for the error, dependent on parameters: w/τG, T ,







where Cd is a constant that depends only on the dimensionality.
The two expressions for the error share the same functional
dependence on w/τG, T , D and S. The ratio between the two
expressions is approximately a constant as a function of δs only
for d = 1 and d = 2, while significant deviations are observed in
higher dimensions.
The dependence of the error on the simulation parameters
becomes more transparent if ε is expressed as an explicit function
of the total simulation time. Consider in fact a free energy profile
F (s) that has to be filled with Gaussians up to a given level Fmax
, for example the free energy of the lowest saddle point in F (s).
The total computational time needed to fill this profile can be
estimated as the ratio between the volume that has to be filled
and the volume of one Gaussian times τG :


















D is the average time required for the CVs to diffuse


















is a function of δsS and of the dimensionality alone. Eq. 1.38 states
that the error of a metadynamics reconstruction is inversely pro-
portional to the square root of the total simulation time, measured
in units of the diffusion time. The error will be large for slowly dif-
fusing systems, in which the walker takes a long time to explore
the CVs space.
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1.5 advanced md simulation methods
1.5.1 MM-PBSA
one of the major goals of the computational chemistry is to de-
velop methods to accurately predict the binding eergy of a ligand
to a protein. This is of central interest in medicinal chemistry,
because the action of most drugs (inhibition, activation etc.) is
caused by the binding of the drug to its target receptor. However,
many biochemical problems can be treated in a similar way For
example, the reactivity of an enzyme can be estimated by com-
paring the free energy of the reactant and tranisition states of
the active site in protein. Therefore, many methods have been
developed with this aim [? ? ]. MM-PB(GB)SA method is another
free energy calculation method(107). Unlike other free energy
calculation methods like free energy perturbation (FEP) or Ther-
modynamic Integration(TI) method, this is the post-processing
method, which means it calculates the free energy based on
existing structure snapshots. MM-PBSA restrict the molecular
simulations to the states before and after the binding process.It is
an attractive approch because it does not contain any parameters
that var for different ligands-receptor systems and it involves a set
of physically well defined term: The binding affinity is estimated
from the free energies of the receptor, the ligand and the complex.
In MM-PB(GB)SA calculation, the free energy of the system is
divided into three parts: molecular mechanics energy(MM), and
non polar solvation free energy (SA). The MM energy usually
consists of electrostatic energy and vander walls energy of the
system in vacuum. In some applications the bond energies, an-
gle energies, and dihedral angle energies are also included in
MM energy. the entropy of the system can be included by using
normaol mode analysis or other methods.
In this method to estimate the free eergy of the complex sys-
tem, one carries out a molecular dynamics simulation, typically
in a periodic box with water and counter ions, and correct rep-
resentation of long-range electrostatic effects, saving a set of
representative structures. then one post process these structures,
remove any solvent and counter ions molecules, and calculates
the free energy, G, accordign to the following equation:
4Gbind = 4EMM +4GPBSA − TSMM (1.39)
or
4Gbind = Gcomplex − (Greceptor +Gligand) (1.40)
where4Gbind is the calculated average free energy, and4EMM
is the average molecular mechanical energy,Gcomplex,Greceptor,
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and Gligand are the free energies of the complex, the protein,
and the ligand, respectively.
For each system, the free energy can be estimated in terms of
molecular mechanic potential energy EMM, the solvation free
energy Gsolv, and the entropic contribution (TS) as fallows:
Gbind = EMM − TS+Gsolv (1.41)
EMM = Einternal + Eelec + EvdW (1.42)
Einternal = 4Ebond +4Eangle +4Etors (1.43)
Gsolv = Gelec,solv +Gnonpolar,solv (1.44)
where these correspond to the bond, angle, torsion, van der
waals, and electrostatic terms in molecular mechanical force field,
evaluated with no non-bonded cutoff. All the terms in Eq. 1.42 are
averages of energies obtained fron a number of snapshots taken
from the MD simulations [? ]. In order to reduce the the time
consumption and to obtain the stable energies, the same geometry
is normally used for all three reactants (complex, receptor,ligand),
i.e only the complex is explictily simulated by MD.There by,
Einternal cancels in the clculation of 4Gbind. The MM-PBSA
methos has been successfully applied to many systems [? ? ],
[? ? ? ]. Gpbsa is the solvation free energy calculated with the
numerical solution of the Poisson-Boltzmann equation and an
estimated of the non-polar free energy with the simple surface
area term. The nonpolar solvation contribution is estimated as
GSnonpolar,solv = γA+ b (1.45)
Where A is solvent-accessible surface area and the solvent param-
eters, γ and b, are 0.00542 kcal/mol Å2 and 0.92 kcal/mol, respec-
tively.the probe radius of the solvent was set to 1.4 . the atomic
radii of of the solute were taken from PARSE parameter set [? ? ].
−TSMM is the solue entropy, which can be estimated by quasi
harmonic analysis of the trajectory or by using normal-mode
analysis (108). the solvant entropy is included tin the solvation
free energy term. The free energy due to ionic strength effects
can be added with a continuum approch.
The ability to accuratly calculate 4G, the average free energy,
we can calculate 4G for a given macromolecular system in vari-
ous different confermations or structures, adds a very important
methodology to our computational arsenal. This has been pos-
sible before with free energy perturbation but only for small
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systems and very limited conformational or topological changes.
By using continuum model, it is implicity integrating out all
the solvent coordinates and simplifying the problem. Also, by
calculating the absolute free energy directly with eq 1.2 between
the two “end points” instead of calculating the relative free en-
ergy along a mapping coordinate, we are avoiding computations
of eq 1.1 will have intrinsically much larger errors than free en-
ergy perturbation/thermodynamic integration calculations. What
is surprising is that, despite these larger uncertainties, we can





























Viruses  belonging  to   the  Flaviviridae   family,  which  encloses   the   three  genera Hepacivirus,  Flavivirus  and 
Pestivirus, are responsible for severe disease in humans and animals[1­4] . Among the Hepaciviruses, Hepatits 
C Virus (HCV) is  the frequent cause of acute and chronic hepatitis,   liver cirrhosis and hepatocellular car ­
cinoma worldwide, and creates a significant burden to healthcare systems due to mortality, morbidity and 
treatment costs [5­8]. To give the numbers, hepatitis C (officially recognized as the “silent epidemic”) infected 




analogue  inhibitor   (NI)  ribavirin[12­14],  which  is  effective   in only  about  half  of  patients  who suffer   from 
chronic  HCV   infection,   and  often   produces  toxicity   and  significant   side   effects  .[15,16]   Given   the   high 
prevalence of HCV, there is an urgent need to develop more effective and well tolerated therapies. [17,18]. In  
this respect, new therapeutic lines are following the concept of specifically targeted antiviral therapy for HCV 
(STAT­C),  aiming at directly targeting HCV RNA and viral  enzymes or  influence host­virus interactions (at  
opposite  with   standard   anti­HCV   protocol   which   enhances   natural   immune   responses   to   the   virus)   at 
influencing host­virus interactions [19­21] Namely, novel treatment options now in development are focused 
on  inhibitors  of  HCV­specific  enzymes  NS3  protease   [22­23]  and  NS5B RNA­dependent  RNA polymerase 
(RdRp)[24].   However,   the   emergence   of   resistant  mutations   that   limit   the   use   of   these   compounds   in  
monotherapy complicates the regimens.  Thus, HCV infections are better treated by combination of drugs with 










NNIs   bind   to   one   of   the   at   least   four   allosteric   sites   of   the   enzyme   free   of   (its   natural)   substrate   and 
uncomplexed   with   any   other   non­structural   protein;   they   cause   various   conformational   changes   that 
inactivate   the enzyme,  or   trap  it   in a   functional  conformation  impeding an essential  structural   transition 
between initiation and elongation. [39­40]
The benzimidazole series of NNIs represents a promising group of compounds showing activity against HCV 
and  Bovine  Viral  Diarrhoea  Virus  (BVDV).   [41­43]These   compounds  were   originally   screened   as   specific 
inhibitors of HCV NS5B activity in vitro, but they exhibited marginal potency in cell­based assays, probably  
due   to   poor   cellular   permeability   resulting   from   the   presence   of   a   5­COOH   group   that   is   ionisable   at  
physiological   pH   .   A   1,2­disubstituted   benzimidazole­5­carboxylic   acid   scaffold   was   identified   as   the 

































is  active  against  both  RdRps,   the equivalence between  the mechanisms of  action  is  not  guaranteed.  The 
microscopically based comparison constitutes a valuable starting point for the design of more effective and 
























































imidazole.   The   polypeptide   composition   of   the   column   fractions   was   monitored   by   SDSPAGE.   The 
recombinant RdRps were retained on the column and recovered in the 130­250mM imidazole eluate. These 









incubated  at  30°C for  120 min   then  stopped by  addiction  of  2  ml  of  200mM EDTA.  175ml  of  PicoGreen 
Quantitation Reagent (Molecular Probes), diluted 1/345 in TE, were added to each sample and incubated at  




































































Receptor Simulation length Total atoms Counter ions Box dimension (side, angle)
HCVcomplex 10ns 56092 14Cl 88.9 A, 109.47 dgrees
BVDVcomplex 10ns 55696  17Cl 88.9x88.9x88.9 A;109x109x109
BVDVwild 20ns 55705 17Cl 88.9x88.9x88.9 A;109x109x109









(Salt­Bridge), the cutoff distance is 3 Å. The criterion to determine a  ­  interaction was that the SICD (Shortπ π  







































Compound BVDV HCV­1b BVDV HCV­1b
CC50 
[µM]
EC50 [µM] CC50 [µM] EC50 [µM] IC50 [µM] IC50 [µM]























is  empty.  Furthermore,   the  methyl  group of   the   tail   region of  227G (Figure 1A)  anchors   to   the  extended  










































major   stabilizing   factor   of   227G   is  provided  by   the   strong  hydrophobic   interaction  with   the   receptor   (­
















strengthened   once   the  water­mediated   interaction   comes   into   picture.   Another  HB   is   formed   between 
H18@227G and OG@Ser533 with ADL=2.5  Å  and occupancy of  46%, which creates  a  linkage with loop L3 
(Table3 & Figure10­suppli). We also found a transient HB formed between Ala221 and S1@227G (~occupancy 
12%), further stabilizes 227G in the binding pocket. [Table 3 and Fig 5]

























Occupancy (%) Donar Acceptor ADL*( )Ǻ
80.0 227G­N2 Asp126­OD 2.3
45.0 227G­N5 Ser533­OG 2.5
12.0 Ala­221 227G­S1 2.8
Water­mediated Hydrogen bonds
80 Glu128 WAT 2.2
79 227G­N1 WAT 2.3
                                                        Intra­Hydrogen Bond (HB)
82 Asn273­ND2 Asp126:OD 2.1






involving residues Asp126,  Ser533 and Ala221,  as  well  as  a  salt­bridge between Asp126 and Asn264.  Four   loops L 1,  L2,  L3  and L4  are 



























C1 C3 C4 C5 C6 C7 C10 C11 C12 C13 C14 C15 C17





















C1 C3 C5 C6 C7 C8 C9 C10 C11 C14 C17 O1 O2 S1
A396 L392 L492 V494 T500 P495 V499
BVDV
Residue Ele VdW Total
HCV
Residue Ele VdW Total
Asp126 ­23.8(3.5) ­2.1(0.9) ­25.8(3.3) Val37 0.1(0.1) ­0.3(0.2) ­0.2(0.2)
Arg127 2.2(1.8) ­4.6(1.1) ­2.4(1.9) Leu392 ­1.3(0.6) ­1.3(0.6) ­2.6(1.1)
Glu128 ­3.7(2.7) ­4.4(1.3) ­8.5(3.1) Ala396 0.4(0.7) ­1.8(0.6) ­1.4(1.0)
Arg130 2.3(0.9) ­0.2(0.1) 2.0(0.9) Ile424 ­0.8(0.2) ­0.4(0.1) ­1.1(0.2)
Arg132 8.1(1.7) ­2.2(0.7) 5.9(1.7) His428 ­4.1(1.4) ­3.7(0.8) ­7.8(1.5)
Ala221 ­0.8(1.0) ­1.7(0.6) ­2.5(1.1) Leu492 ­0.5(0.7) ­1.6(0.8) ­2.1(1.2)
Phe224 ­0.1(0.2) ­0.4(0.3) ­0.5(0.2) Val494 ­0.2(0.3) ­2.5(0.6) ­2.7(0.7)
Ile261 ­1.5(0.4) ­4.1(0.8) ­5.6(0.9) Pro495 ­0.2(0.4) ­2.3(0.5) ­2.5(0.6)
Pro262 0.4(0.9) ­5.2(0.7) ­4.8(1.1) Val499 1.2(0.8) ­2.4(0.5) ­1.3(0.9)
Asn264 1.9(0.9) ­2.8(0.6) ­0.8(1.1) Trp500 0.1(0.4) ­5.9(0.7) ­6.0(0.8)
Ala392 ­0.7(0.6) ­1.5(0.4) ­2.1(0.8) Arg503 ­2.6(3.1) ­4.9(0.9) ­7.5(3.5)
Arg503 2.1(2.0) ­4.1(1.2) ­2.0(2.7) Tot ­
11.3(4.6)
­34.0(2.5) ­45.2(5.5)
Tot ­34.0(6.0) ­47.6(3.5) ­81.7(7.3)
Table: 4A Residues wise interaction energy of 227G A)­  BVDV RdRp­227G  B)­ HCV RdRp­227G. 
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flexible protein.  The dynamics of   the apo protein  shows a periodic  behavior  wherein,   initially   the system 
moves deviates to an RMSD of 4.0   upto 10ns, then it steeps down to 3.0    at 12ns . This behavior is repeatedǺ Ǻ  













changes   of   highly   flexible   protein   regions.   The   root­mean­square   deviation,(RMSD)   per   residue   graph, 
(Figure7 ) highlight the regions of protein which show significantly larger flexibility in apo protein as compared 
complex system. Major     region of   interest;  primarily  because they make part  of   the 227G binding cavity; 
wherein the peaks were observed were the Loop L4 region; also known as the linker; and Loop L3.  As already  
mentioned, Loop L4 and L3 along with L2 and L1 constitute the binding cavity.  In the complex (227G­BVDV),  
227G interact  with the residues,   in particular  makes strong HB with Asp126,  and another  residue Glu128 








  We calculated and compared the area of the cavity mouth in the crystal  structure of  BVDV RdRp,  in the 
structure of the Apo after relaxation and in the equilibrated configuration of the complex. In order to calculate 
this  area,  we  considered   the   triangle  defined  by   the   lines  connecting   the   terminal   residues  of   the   loops 


















In   the   framework   of   our   research   for   antiviral   compounds   of   both   synthetic   and   natural   origin,   a   2­










identify  binding site,  binding mode,  as  well  as   to  have a  deeper  dynamic   insight   into  the mechanism of  





































































Leu392,  Ala395,   Ile424,  Leu425,  His428,  and  Phe429   line   in  Pocket1,   and   residues  Val37,  Leu392,  Ala393, 
Ala396, Leu492, and Val494 form pocket 2 (Figure. 3).  In the apo­enzyme residues Leu30 and Leu31 of the  
alpha­helix of lambda1 loop occupy pocket1 and pocket2, respectively. These interactions are disrupted by the 
presence  of  227G  in   the  complex.   Indeed,  after  10ns  of  MD simulation  arm1 of  227G  (see  Figure.1C  for  




pocket  more  deeply   than   the   residues   located   in   the   tip  of   the   fingertip.   Furthermore,   there   is   another 
hydrophobic   region   in   the   binding   cavity   where   the  methyl   group   of   227G   tail   anchors   the   227G   by  
establishing strong interaction with Trp500 and Val499, thereby providing further stability. The benzimidazole 




























inactive or   low active against  BVDV can be surprisingly active against  HCV. Despite the promising results  








improved   inhibitors.   Hopefully,   these   forthcoming   results   will   contribute   to   deciphering   the  molecular 

















































































































































































In   this   preliminary   study   three   new   classes   of  RNA­dependent   RNA  polymerase  (RdRp)   of   Flaviviridae 
inhibitors, the linear N­tricyclic systems derived by condensation of the quinoline nucleus with 1,2,3­triazole, 
imidazole   or   pyrazine   (obtaining   triazolo[4,5­g]quinolines,   imidazo[4,5­g]quinolines   and   pyrido[2,3­











energies  of  227G in  both  HCV and BVDV RdRp.  Calculated binding  free energies  were then converted to 
computational IC50 which were then compared with the experimentally available IC50 values









and GBV­C or hepatitis  G virus,  while at  present not formally classified within the Hepacivirus genus, are 
closely   related   to   HCV   and   represent   unassigned  members   of   Flaviviridae.  Within   this   family   are   also 
comprised the  Flavivirus  genus, with viruses such as Dengue Fever, Yellow Fever  (YFV), West Nile, Japanese 
encephalitis   and   tick­borne   encephalitis,   and   the  Pestivirus  genus,  which   includes  bovine   viral   diarrhea 












cause   a   range   of   clinical  manifestations   including   abortion,   teratogenesis,   respiratory  problems,   chronic 
wasting disease, immune system dysfunction and predisposition to secondary viral and bacterial infections. 
BVDV can also establish a persistent infection (PI) in animals that remain viremic throughout life and serve as  
continuous   virus   reservoirs.8  Persistently   infected   animals   often   succumb   to   fatal   mucosal   disease. 
Furthermore, BVDV shows the ability to cross the placenta of susceptible animals causing a variety of fetal 
infections.9
In  conclusion  currently,  with   the  exception  of  YFV,  no  vaccine  exists  against   the  various  Flaviviridae 
members;   furthermore  there   are  no  antiviral  pharmaceuticals   to  prevent  or   treat  Flavivirus  or  Pestivirus 
infections and the association of interferon and ribavirin has limited efficacy in HCV therapy. Therefore new 
drugs for  therapy and chemoprophylaxis are clearly  needed for   infections and diseases caused by viruses  
belonging to the Flaviviridae family.
Recently  we   reported   the   synthesis  of   the   [4,7]phenantroline  nucleus,   an  angular  N­tricyclic   systems 
derived by expansion of the quinoline nucleus with pyridine, and of several related derivatives which emerged 
30
as a new class of antiviral agents endowed with both  in silico and  in vitro  activity against viruses ssRNA+.10 




















systems  1k­m,  2d­q,  3d­f,  4j  and  5m­o  of Figures 1­3. All the new compounds were submitted to the same 




















inhibitor complex,   large ribosomal subunit,  and  inhibitor  snapshots were taken from the snapshot of  the 
performed MD trajectory.  According  to   the MM­PBSA method[15,16]  binding  free  energy   ( G∆ bind)  of  each 
system could be conceptually summarized as follows
                    G∆ bind = Gcom ­ Grec ­ Glig                                    (1)
                 G =  E∆ ∆ MM +  G∆ solv ­ T S                                                  ∆  (2)
   In which 
E∆ MM =  E∆ bond +  E∆ angle +  E∆ torsion +  E∆ vdw +  E∆ EEL                                  (3)
                     G∆ solv =  G∆ PB +  G∆ SA                                                       (4)
                         G∆ SA = γSA + b                                                                   (5)
where Gcom, Grec, and Glig are the free energy for the complex, receptor, and ligand (inhibitor), respectively. Each 
term is calculated by averaging the energy of molecular mechanics ( E∆ MM), the solvation free energy ( G∆ solv), 




G∆ solv  (4) is the solvation free energy given by  G∆ PB, polar solvation free energy evaluated using the Poisson­
Boltzmann equation, and  G∆ SA, nonpolar contribution to solvation free energy from the surface area.29 The 
electrostatic solvation free energy was calculated using DELPHI[22,23] software, with low dielectric medium 
for solute ( =1) and high dielectric medium for solvent ( =80). Atomic radii were taken from PARSE29 with anε ε  
additional value of 1.90 Å for phosphorus,[24] and in order to be consistent with molecular mechanics energy 
calculation, the partial charges on solute were taken from the Amber 99 force ﬁeld[21] and from our ab initio  


























                                VG(s(x), t) )    =     W             exp (­(s(x) – sG(t ))∑ ′ 2/2( s)δ 2)                (1)
























































adopt the same scheme (soft  particle mesh Ewald schemes26) as for the simulations.  The conﬁgurational  




























































Residue Ele VdW Total
Arg127 ­10 ­2.4 ­12
Glu128 ­1 ­2.1 ­3.1
Ala221 ­0.1 ­1 ­1
Ile261 2 ­3.4 ­1.4
Pro262 ­7.8 ­2.3 ­10.2
Asn264 ­0.5 ­4.2 ­4.8




solvent.  These simulations were used to identify alternative stable binding pose,   if  present other than the 
initial   docking   structure,   and   to   predict   the   energetics   of   unbinding.  The   free   energy   simulations  were 
performed as a function of two collective variable that took into account the hydrophobic contacts and the  
distance between the center  of mass of the inhibitor  with the center of mass of the binding cavity.  These 
variables  have  been  already  used   to  characterize   ligand­target  molecular   recognition processes  using  the 
metadynamics approach. 
Interestingly,  we   found   that   in   case   of   PS1036,the   deepest  minima   corresponded   to   the   initial   starting 












































interactions   between  Glu128   and  N3@PS999   and  Arg127   and  O2@PS999:   although   the  mediating  water 











of  PS999  occurs  around  its  major   inertia  axis.  This   leads   into   the   first   event  observed   in   the  undocking 

















































imply a high barrier  to  go from mini1 to mini2.  With the visual   inspection of  FES the free energy barrier 
obtained was ~9kcal/mol to go from mini1 to mini2. 
Table2: Interaction Energy of key residues in PS1036­RdRp complex  (Kcal/mol)
Residue Ele VdW Total
Arg127 0.3 ­5.4 ­5.1
Ala221 ­1.2 ­0.9 ­2.4
Ile261 1.3 ­5.4 ­4.2
Pro262 ­6.4 ­2.1 ­8.4
Asn264 ­4.7 ­1.9 ­7


















mini2   ~0.43Å.   These   values   are   very   well   evident   of   loss   of   stability   of   PS1036   from  mini1   to  mini2.  










in  case of  PS1036  it  moved out   from Loop L1 and Loop L4.  The undocking or  escape of   the  inhibitor   is 
42












binding mode of   inhibitors   to   the  receptors  could  be acquired.  Nevertheless,   there are  number  of   issues  
related with MM­PBSA that needs careful consideration when one wants to employ this method, and one of 
them  is   to   justify   the  necessity   to   evaluate   snapshot  of   the  complex,   receptor  and   ligand   from a   single 
trajectory or running separate trajectories for all three term. The single trajectory method has an apparent 







Generally speaking,  and in harmony with out previous findings of our group (28,29,30,).  According to this  
computational perspective, Table3, electrostatic ( GΔ E) and VdW ( GΔ VdW) terms in the gas phase provide the 





( GΔ Etot) and non­electrostatic ( GΔ NPtot) contributions in Table3 .  As demonstrated by numerous studies, the 
electrostatic   contribution   generally   disfavors   the   docking   of   ligand   and   receptor  molecules   because   the 
unfavorable change in the electrostatic of solvation is mostly,  but not fully,  compensated by the favorable  
electrostatic  within   the   resulting   ligand­receptor   complex.   Indeed,   from  Table3,  we   can   appreciate   that, 
despite the favorable electrostatic energies in gas phase ( GΔ E), which are ­4.5 and ­4.6 in PS999 and PS1036 
respectively, the contribution of the polar solvation energies to binding which are 24.3 and 22.9 in PS999 and 
PS1036 respectively, the sum of  GΔ EL and  GΔ PB, does not favor the binding. Table 3 also suggests that the net 
result of non electrostatic interactions ( GΔ NP), the sum of  GΔ vdw and  GΔ NP, is favorable for the formation of the 
complexes, and it should be noted that this behavior has been proposed previously as a general trend for the  









































































System EΔ VDW EΔ EL GΔ PB GΔ NP PBtot GΔ EL+PB GΔ vdw+NP T SΔ solute HΔ GΔ a/ GΔ b IC50a/IC50b
PS999 ­30.0(±2.7) ­18.6(±5.2) 24.3(±5.5) ­4.6(±0.7) ­28.8(±3.1) 5.7(±5.2) ­34.6(±2.8) ­18.4(±2.5) ­28.9 ­10.5/­9.8 0.02/0.06
PS999m ­28.6(±2.9) ­17.9(±4.3) 21.8(±4.8) ­4.4(±1.2) ­25.2(±3.3) 5.9(±3.9) ­33.0(±1.8) ­18.3(±2.1) ­27.1 ­6.9 1.6
PS1036 ­28.3(±3.2) ­20.2(±2.3) 22.9(±5.1) ­4.5(±0.19) ­26.6(±2.8) 2.9(±3.2) ­32.8(±1.2) ­18.3(±2.8) ­29.9 ­8.9/­8.1 0.2/1.0















































Binding  free energies  of   the NNI­BVDVRdRp complex were calculated which showed similar   trend to  the 
corresponding experimatal IC50 values for both the complexes.   This was an encouraging performance and 





















































































































three   reported   HCV   NS5B   NNI   binding   site   represented   by   (A)   Benzofurans     (B)   N,N­disubstituted 
phenylalanine and (C) benzothiadiazine  inhibitors was examined for the binding of the compounds. We then 
used all atom standard molecular dynamics (MD) simulations to investigate the most probable binding site for 
the compounds as in both the complexes,  there was a dissociation in two out of the three cavities  under  
investigation. Therefore, Identifying the binding cavities and orientation of our compounds can help us to 







four   to   five   times more prevalent   than HIV­1,  with  over 200 million cases  globally,  of  which $4.1  million 
infections exist  in the United States alone.  Despite its   large medical and economical  impact,  there are no 
vaccines or efficient therapies without major side effects. The problems faced in HCV research are manifolds. 




reasons,   high   costs,   and   the   inherent   difficulties   in   working   with   large   animals   severely   limit   their  
experimental  utility.  However,  the greatest   limitation for  HCV research has been the lack of  a cell  culture 
system that supports   the efficient  and reliable  propagation of   the virus.  Among  limited options the most 
effective therapy which include Type I interferons (IFNs), IFN  and IFN , are crucial and potent componentsα β  
of the early host response against virus infection[3]   and recombinant (pegylated) IFN 2a and IFN 2b areα α  
widely used for the treatment of CHC and chronic hepatitis B. The current standard treatment of CHC with  





the   focus  of   intense  drug  discovery   activity   as   they   are   considered  as   significant   targets   for   therapeutic 
intervention. Several reasons that makes HCV RdRp an excellent target for antiviral investigation include: 1)­  
Successes   stories   in   targeting   the   polymerases   from   other   viral   systems   such   as   human 




hence   it  makes   it   a   interesting   target   for   fighting  HCV   infection;  3)­   extensive   functional  and   structural  
characterization   (The   high­resolution   three­dimensional   crystal   structures   of   the   NS5B     polymerase   is  





different   conformations.  The   conformations  more   frequently   seen   in   crystal   structure   correspond   to   the 
“closed” or the “active” state where the the loops extending from the finger domain are in contact with the 










have   remained  unchanged   certain   sequences  of   their  RdRp,  by   virtue  of   the   key   role   in   the  process  of  


















palm domain   (fig  1,   site  C  and  site  D)[11,12].  Benzofuran  compound HCV­796  has  been  shown  to  have 
significant   antiviral   effects   in   patients   chronically   infected   with   HCV[13,14].   In   addition   two   series   of 
compounds based on the thiophene and benzimidazole (fig 1) scaffolds have been reported to inhibit NS5B by 
binding to two different binding pockets in the thumb domain of NS5B(site A and site B) [15,16]. NNI's have  
there  own set  backs   including  adverse  side  effects   rapid  selection  of   resistant  virus  mutant,  or  naturally  




















CC50 EC50 SI BVDV HCV
PS1126 >100 5.8 >17 97 2
PS1097 >100 6 >16 40 4




Since   we   were   clueless   regarding   the   binding   site   of   the   three   classes   of   inhibitors   viz,  





Compounds   belonging   to   N,N­disubstituted   phenylalanine,[27,28],   thiophene,[29,30],   thiazol­one   [31,32] 
dihydropyrones,[33,34]and acyl pyrrolidine [35,36] molecular scaffolds occupy a common binding site in the 
thumb subdomain ( 35∼ Å  from the polymerase active site), denoted by site 'B' in fig1. Likewise, compounds 

















































                    G∆ bind = Gcom ­ Grec ­ Glig                                    (1)
                 G =  E∆ ∆ MM +  G∆ solv ­ T S                                                    (2)∆
in which:
E∆ MM =  E∆ bond +  E∆ angle +  E∆ torsion +  E∆ vdw +  E∆ EEL                             (3)
                     G∆ solv =  G∆ PB +  G∆ SA                                                           (4)
                         G∆ SA = γSA + b                                                                   (5)
Gcom, Grec, and Glig are the free energy for the complex, receptor, and ligand (inhibitor), respectively. Each term 
is calculated by averaging the energy of molecular mechanics ( E∆ MM), the solvation free energy ( G∆ solv), and the 
vibrational   entropy   term   (T S)   as   in   (2).   E∆ ∆ MM  (3)   denotes   the   average   molecular   mechanics   energy 
contributed   by   bonded   (Ebond,   Eangle,   and   Etorsion)   and   nonbonded   (Evdw  and   EEEL)   terms.  The   nonbonded 
contribution of the binding pockets were further evaluated on a residue basis using MM­PBSA.
G∆ solv  (4)   is   the   solvation   free   energy   calculated  by   summing  polar   ( G∆ PB,   evaluated  using   the  Poisson­
Boltzmann equation) and nonpolar ( G∆ SA, proportional to the surface area, 3) terms.  G∆ PB was calculated using 
the  DELPHI[65,66]  package,  with   low dielectric  medium  for   solute   ( =1)  and  high  dielectric  medium  forε  
solvent ( =80). Atomic radii were taken from PARSE [64] with an additional value of 1.90 Å for phosphorus[67],ε  
while  partial  charges  on solute  were  taken   from the  Amber  9   force ﬁeld,   the same used  to  perform MD 
simulations. An 80% boxﬁll lattice with grid spacing 0.5 grid/Å was applied, and 10,000 linear iteration steps 





















carboxylic  acids[27,20],  cyclopentylethyl­phenoxy  acrylic  acids[42],  site  C benzothiadiazines[38],  reversible 
arylsulfonyl rhodanines[39] and Site D[13,14,15] known till date [Fig­1]. In the absence of knowledge regarding 



























Apart   from  following  a  normal  procedure  of  picking  up  orientations  on   the  basis  of  high  population  of  
conformers and low energy, we also did a thorough investigation of each conformer from the clusters obtained 
on the basis of their vicinity to the resistance mutations as well as the interactions made by the compounds  














compounds  [11,12].   In contrast   to   the broad open surface exposed  in  the palm1 binding pocket   is  deep,  
narrow,  and  enclosed  descending   from  the  palm  C  binding   site.  NNI  binding   site   in  palm2  has  unique 
structural features. The deep enclosure within the core of the conserved and highly structured palm domain,  
featuring narrow entry and exit portals.The cavity is predominantly hydrophobic in nature. Its an elongated 
and highly  enclosed pocket  present   in   the palm domain of  HCV RdRp.   It   lies  between primer  grip motif 
(residue I363­N369) and beta sheets (residue P214­Y219, D319­G325).[15]. According to the data obtained by 
the x­ray crystallographic structure FQK[15], the pocket is formed by residues Gly557, Gly449, Gly554, Tyr448,  
Gln199,  Val201,   Leu204,   Ile323,  Leu314,   Ser365,  Phe203,  Asp319,  Asn316,  Tyr195,  Phe193,  Val321,  Arg200, 
Pro197, Leu360 and Ile363. Total interaction energy between PS1126 and the binding pocket was calculated as 
described in material and method. The total energy came out to be ­32.6 kcal/mol. Fig. 3b   summarizes the 











Residue Ele VdW Total
Phe193 ­0.5(±0.3) ­2.4(±0.8) ­2.9(±0.9)
Arg200 1.5(±2.1) ­6.0(±1.0) ­4.3(±2.4)
Leu204 ­3.4(±0.4) ­2.0(±0.5) ­2.3(±0.6)
Leu314 0.7(±0.2) ­3.3(±0.5) ­2.6(±0.6)
Asn316 ­2.4(±1.2) ­4.1(±0.7) ­6.4(±1.2)
Asp318 ­2.0(±0.5) 0.2(±0.0) ­2.1(±0.7)
Asp319 ­3.1(±1.4) ­2.0(±0.6) ­5.0(±1.5)
Val321 ­0.3(±0.2) ­1.1(±0.4) ­1.4(±0.5)
Ser365 ­0.8(±2.2) ­2.0(±0.5) ­2.0(±2.1)
Ser366 ­0.7(±0.6) ­2.8(±0.7) ­3.5(±1.0)





















cavity,   as   can be  seen   in  Fig??.  The  residues  undergo conformational  changes,   including  breaking  of  HB 
between Arg200 and Asn316, allowing passage for entry of PS1126 into the cavity. (FIG). 
In order to further explore events which lead to the opening of the buried cavity C, we superimposed average  









population states for torsions of residue Arg200. The atoms forming ramachandran  torsions ( , Φ Ψ) are :   Φ torsion are:CB­CG­CD­NE; and 
  Ψ torsion are : CG­CD­NE­CZ. The Ramachandran dihedral illustrating the change in the side chain dihedral angles upon ligand binding. 












was  more  pronounced   in  dihedral  CG­CD­NE­CZ,  wherein   ,   the   side  chain   in   case  of  Apo  occupied  an 
altogether different conformation space as compared to the complex systems. All these, study supported the 















average   structure   from   the   equilibrium   of   20ns   MD   simulation.   The   Binding   site   residues   are   shown   here   using   sticks  





Residue Ele VdW Total
Phe193 1.9(±0.4) ­4.0(±0.6) ­2.0(±0.6)
Ser196 ­1.0(±1.0) ­1.3(±0.5) ­2.1(±1.0)
Pro197 ­0.2(±0.2) ­2.0(±0.4) ­2.0(±0.4)
Arg200 ­4.5(±2.4) ­3.5(±0.7) ­8.1(±2.6)
Asn316 ­1.4(±1.2) ­1.5(±0.4) ­3.0(±1.2)
Asp318 ­1.9(±0.6) ­0.1(±0.1) ­2.0(±0.7)
Asp319 ­2.0(±0.7) ­0.1(±0.0) ­2.1(±0.7)
Tyr448 0.3(±0.8) ­8.0(±0.8) ­8.0(±1.2)
Phe551 ­0.6(±0.5) ­3.0(±0.7) ­3.3(±0.7)
Ala553 ­1.0(±0.4) ­0.4(±0.4) ­1.4(±)
Tyr555 ­0.3(±0.3) ­1.5(±0.4) ­2.0(±0.5)
Table2: Interaction Energy of key residues in PS1101­RdRp complex  (Kcal/mol)
PS1101   stabilities   itself   into   the   cavity   by  making   a   strong   hydrogen   bond  with   the  N3@   PS1101   and 
HD@Cys316.  The HB persist  throughout  the 20 ns simulation with  an occupancy of  more than 65% with  
average dynamic length ~2.8A . Owing to the highly hydrophobic nature of the cavity the major contribution to 
the total interaction energy (­34Kcal/mol) is provided by the hydrophobic interactions (­25.0 kcal/mol). The 
residue wise contribution to the energy is  listed in table2.  Residue Tyr448 belonging to the  β  hairpin loop 
makes maximum hydrophobic interaction (­7.9 kcal/mol)  with PS1101.  In depth analysis  of  the trajectory 
revealed   that  a   strong   ­π π  stacking  exist  between  the  phenyl   ring  of  Tyr448  and  PS1101   throughout   the 
simulation   thereby  providing   additional   stability   to   PS1101   into   the   binding   cavity.   Additionally,   Arg200 
provides further support to PS1101 into the binding cavity by contributing favorably to the TOT interaction 




PS1097 accommodated itself   in cavity which can be characterized as an extended Site C.   The wall  of the 
binding cavity include residue from the palm and the thumb domain. The cavity is overlapping but more 
buried with the one of PS1101.  Predominantly,   the major  interactions occur between PS1097 and the the  
residues of Beta hairpin loop, inner core of the thumb domain and the primer grip.
Figure6: Expanded view of interaction between key residues of binding cavity of PS1097, PS1101 and PS1126. Snapshot taken from the 
average   structure   from   the   equilibrium   of   20ns   MD   simulation.   The   Binding   site   residues   are   shown   here   using   sticks  




Residue Ele VdW Total
Arg386 ­9.9(±1.5) ­1.7(±0.4) ­11.7(±1.7)
Thr390 ­1.7(±0.6) ­1.1(±0.3) ­2.8(±0.7)
Pro391 ­1.6(±0.4) ­2.3(±0.5) ­4.1(±0.7)
Glu398 ­5.4(±1.0) ­0.2(±0.1) ­5.5(±1.1)
Ser407 ­2.0(±0.8) ­1.6(±0.4) ­3.5(±1.3)
Asn411 2.7(±1.2) ­4.4(±0.8) ­2.0(±1.3)
Met414 ­0.1(±0.3) ­4.1(±0.6) ­4.2(±0.6)
Tyr415 1.6(±0.3) ­3.0(±0.4) ­1.2(±0.4)
Gln446 ­1.2(±0.8) ­0.5(±0.1) ­2.0(±0.8)
Ile447 ­2.4(±0.5) ­2.0(±0.3) ­4.0(±0.8)










binding site   residues  we  performed  interaction energy  analysis.  we observed  the   total   interaction  energy 
between PS1097 and the binding pocket of PS1097, came out to be 48 kcal/mol. In PS1097­HCV RdRp system,  
both   electrostatic(­23.3   kcal/mol)   and   VdW(­24.5   kcal/mol)   contributed   all   most   equally   to   the   total 
interaction energy. Major contributors of the hydrophobic contacts(HpH) are from residues Asn411, Met414,  
Pro391,  Tyr448 and Tyr415 while  residues Arg386,  Tyr448,   Ile447 and Glu398 provided strong electrostatic 
interaction crucial for the stability of the PS1097 in the binding pocket. (Table3, Fig 6)
1)­Mechanism of Inhibition:
In case of HCV RdRp the active site is encircled by a     β hairpin loop( A442­Y452) and the C­terminus(L545­
H562) which fold into the cavity.[53,54]. Due to the strategic positioning of the β loop as well as the C­terminus 


























































EΔ EL ­36.0(±1.9) ­42.9(±2.7) ­19.8
EΔ VDW ­52.17(±2.9) ­39.9(±1.8) ­25.9
GΔ PB 24.1(±2.7) 13.7(±3.2) 1.5
GΔ NP ­5.8(±1.2) ­5.6(±0.9) ­4.7
PBtot ­33.9(±3.1) ­29.8(±3.4) ­30.1




T SΔ solute ­18.9(±2.3) ­17.6(±1.8) ­21.6(±2.1)
HΔ ­69.8 ­74.8 0.3
GΔ a ­11.6 ­10.2 ­8.5
GΔ b ­8.8 ­8.1 ­7.7
























for   further analysis.  The binding  free energy  calculated were compared using the MMPBSA approach are 
compared with the experimental free energies of binding (absolute affinities, Table 1;). The calculations predict 
that binding affinities of PS1101, PS1097 and PS1126 are ­12.2 kcal/mol, ­11.6 kcal/mol and ­11.5 kcal/mol  






1(delGpb,  26.1,  24.2 and 33.6 kcal/mol),   the contribution of electrostatic  interactions to the solvation free 
energy   (delGsolv)   is  unfavorable   for   three   inhibitor­protein  complexes(Table2).  Table  2  examine   the   total  











Extensive   Insilico   study   helped   us   to   identify   putative   Binding   cavity   of   the   compounds   belonging   to  


































































































































































































































































drug  designing   in  order   to  understand   the  molecular   recognition  process  with   respect   to  protein   ligand 
system. In a  nut  shell,   identification of  novel  binding site,  estimation of  protein­ligand binding affinities, 














To   the  best   of   our   knowledge,  we,   for   the   first   time   identified   a  benzimidazole  derivative   active   at   low  
micromolar range against both HCV and BVDV RdRp.  Benzimidazole class of compounds were known to bind 
in the thumb domain of HCV RdRp, but no information regarding the binding of same class of compounds was 




























Binding  free energies  of   the NNI­BVDVRdRp complex were calculated which showed similar   trend to  the 
corresponding experimatal IC50 values for both the complexes.   This was an encouraging performance and 
















outcome will  be  a  major  understanding on how the  HCV and BVDV RdRp could  be  targeted by specific  
inhibitors, thus allowing a rational (in silico) drug design.
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